NEXT Financial Group Inc Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

NEXT Financial Group Inc lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 67.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,465 shares of the biopharmaceutical company’s stock after selling 19,485 shares during the period. NEXT Financial Group Inc’s holdings in Gilead Sciences were worth $615,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. LeJeune Puetz Investment Counsel LLC lifted its stake in shares of Gilead Sciences by 0.6% during the third quarter. LeJeune Puetz Investment Counsel LLC now owns 26,385 shares of the biopharmaceutical company’s stock valued at $1,672,000 after buying an additional 155 shares during the period. Cornerstone Wealth Management LLC lifted its stake in shares of Gilead Sciences by 3.6% during the third quarter. Cornerstone Wealth Management LLC now owns 4,962 shares of the biopharmaceutical company’s stock valued at $314,000 after buying an additional 174 shares during the period. Unison Advisors LLC lifted its stake in shares of Gilead Sciences by 1.0% during the fourth quarter. Unison Advisors LLC now owns 18,342 shares of the biopharmaceutical company’s stock valued at $1,192,000 after buying an additional 177 shares during the period. Municipal Employees Retirement System of Michigan lifted its stake in shares of Gilead Sciences by 0.5% during the third quarter. Municipal Employees Retirement System of Michigan now owns 33,530 shares of the biopharmaceutical company’s stock valued at $2,125,000 after buying an additional 180 shares during the period. Finally, Larson Financial Group LLC lifted its stake in shares of Gilead Sciences by 30.7% during the third quarter. Larson Financial Group LLC now owns 826 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 194 shares during the period. 79.27% of the stock is currently owned by institutional investors.

In other news, EVP Brett A. Pletcher sold 15,000 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $66.85, for a total value of $1,002,750.00. Following the completion of the sale, the executive vice president now owns 32,064 shares of the company’s stock, valued at $2,143,478.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Brett A. Pletcher sold 4,000 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $64.52, for a total transaction of $258,080.00. Following the completion of the sale, the executive vice president now directly owns 23,921 shares of the company’s stock, valued at approximately $1,543,382.92. The disclosure for this sale can be found here. Insiders sold 45,622 shares of company stock valued at $2,986,438 in the last three months. Company insiders own 0.20% of the company’s stock.

A number of equities analysts have weighed in on the stock. Cowen reaffirmed a “buy” rating and set a $85.00 price target on shares of Gilead Sciences in a research note on Thursday, January 2nd. Oppenheimer raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating in a research note on Friday, January 3rd. Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. Bank of America assumed coverage on shares of Gilead Sciences in a research note on Wednesday, October 16th. They set a “neutral” rating and a $70.00 price target on the stock. Finally, Robert W. Baird set a $76.00 price target on shares of Gilead Sciences and gave the stock a “hold” rating in a research note on Friday, October 25th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Hold” and an average price target of $78.91.

Gilead Sciences stock opened at $63.94 on Friday. Gilead Sciences, Inc. has a 52-week low of $60.89 and a 52-week high of $70.50. The firm has a fifty day moving average of $65.45 and a 200-day moving average of $65.05. The firm has a market capitalization of $80.25 billion, a P/E ratio of 30.59, a PEG ratio of 3.85 and a beta of 1.11. The company has a quick ratio of 2.87, a current ratio of 2.96 and a debt-to-equity ratio of 1.11.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.01. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. The company had revenue of $5.60 billion during the quarter, compared to analyst estimates of $5.61 billion. During the same quarter in the prior year, the business earned $1.84 earnings per share. The business’s quarterly revenue was up .1% compared to the same quarter last year. On average, research analysts expect that Gilead Sciences, Inc. will post 6.63 EPS for the current fiscal year.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: Diversification in Your Portfolio

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.